💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sildenafil

CHEMBL192 Phase 4 Zugelassen Small molecule
Half-Life
4 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
474.6 g/mol
LogP
1.5
Phase
4

Cardiovascular research, not sexual medicine, produced sildenafil, a selective inhibitor of phosphodiesterase type 5. Preventing the breakdown of cyclic GMP sustains the second messenger that relaxes vascular smooth muscle, so blood vessels dilate and flow increases. Two indications follow from the same mechanism applied to different vascular beds: erectile dysfunction, and pulmonary arterial hypertension where the aim is to lower pressure in the pulmonary arteries. Concurrent nitroglycerin is recorded as a major interaction, because nitrates and PDE5 inhibition act on the same cGMP pathway and together can precipitate severe hypotension. The compound has a half-life near four hours and the formula C22H30N6O4S, about 474.6 g/mol.

Originally developed for heart conditions, this medication relaxes and widens blood vessels by blocking an enzyme called PDE5, increasing blood flow. It is used both to treat erectile dysfunction and, at different doses, to lower abnormally high blood pressure in the arteries of the lungs (pulmonary arterial hypertension).

Molekularmasse

474,5800 g/mol

LogP

1,50

TPSA

118,00 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Urology Hypertension

Arzneimittelklassen

G — G - Genito-Urinary System and Sex Hormones

Wirkmechanismus

Selective PDE5 inhibitor increasing cGMP.

Pharmacokinetics (PK)

Half-Life 4 hours

Pharmacodynamics (PD)

Mechanismus

Selective PDE5 inhibitor increasing cGMP.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12

                

                

                
                

                    
InChI

                    
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H30N6O4S

                    

                    
                    

                        
HBD / HBA

                        
1 / 8

                    

                    
                    

                        
Rotierbare Bindungen

                        
7

                    

                    
                    
                    

                        
Schwere Atome

                        
33

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            PDE5A (Phosphodiesterase 5)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            CYP3A4 (Cytochrome P450 3A4)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Sildenafil + Tamsulosin
                            
                        

                        
                        
Combining tamsulosin (alpha-1 blocker) with sildenafil (PDE-5 inhibitor) produces additive vasodilation, substantially increasing the risk of symptomatic hypotension, dizziness, and syncope.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Sildenafil + Nitroglycerin
                            
                        

                        
                        
Combining sildenafil with nitrates causes profound, potentially fatal hypotension; this combination is absolutely contraindicated.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
Originally developed for heart conditions, this medication relaxes and widens blood vessels by blocking an enzyme called PDE5, increasing blood flow. It is used both to treat erectile dysfunction and, at different doses, to lower abnormally high blood pressure in the arteries of the lungs (pulmonary arterial hypertension).

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective PDE5 inhibitor increasing cGMP.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Sildenafil: Half-life: 4 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Sildenafil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Tamsulosin
                            Small molecule
                        
                        
                        
                            Finasteride
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL192.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 135398744.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.